Written questions by Gardner.

What progress his Department has made on reviewing the funding of research to improve (a) treatment and (b) outcomes for people diagnosed with lobular breast cancer.

The Department spends £1.5 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR), with cancer being the largest area of spend at over £121.8 million in 2022/23. The NIHR spends more on cancer than any other disease group, reflecting its high priority. Our investments in cancer, including lobular breast cancer, are pivotal to informing efforts to improve cancer prevention, treatment, and outcomes.We are proud to have invested £29 million into the Institute of Cancer Research and the Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, including lobular breast cancer. This is complemented by wider investments into breast cancer research including, for example, a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, again including lobular breast cancer.The NIHR continues to encourage and welcome applications for research into any aspect of human health, including lobular breast cancer. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

What steps his Department is taking to increase the provision of ADHD services across North Staffordshire.

The Department is currently considering next steps to improve access to attention deficit hyperactivity disorder (ADHD) services. It is the responsibility of integrated care boards (ICBs) to make appropriate provision to meet the health and care needs of their local population, including ADHD care pathways, in line with relevant National Institute for Health and Care Excellence guidelines.We are supporting a taskforce that NHS England is establishing to look at ADHD service provision and its impact on patient experience. The taskforce will bring together expertise from across a broad range of sectors, including the National Health Service, education, and justice, to better understand the challenges affecting people with ADHD, and to help provide a joined-up approach in response to concerns around rising demand.The Staffordshire and Stoke-on-Trent ICB advises that it has commissioned a new adult ADHD diagnostic and treatment pathway which began in July 2023. The ICB is working closely with its provider trusts to implement the new pathway.